ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

ClinicalTrials.gov ID: NCT05113745

Public ClinicalTrials.gov record NCT05113745. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Assess the Long-term Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy

Study identification

NCT ID
NCT05113745
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Enrollment
68 participants

Conditions and interventions

Interventions

  • AXS-12 (reboxetine) Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
15 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 19, 2021
Primary completion
Nov 14, 2024
Completion
Nov 14, 2024
Last update posted
Nov 12, 2025

2021 – 2024

United States locations

U.S. sites
24
U.S. states
12
U.S. cities
23
Facility City State ZIP Site status
Clinical Research Site Phoenix Arizona 85054
Clinical Research Site Boulder Colorado 80301
Clinical Research Site Colorado Springs Colorado 80918
Clinical Research Site Brandon Florida 33511
Clinical Research Site Clearwater Florida 33765
Clinical Research Site Doral Florida 33122
Clinical Research Site Miami Lakes Florida 33016
Clinical Research Site Winter Park Florida 32789
Clinical Research Site Atlanta Georgia 30315
Clinical Research Site Atlanta Georgia 30328
Clinical Research Site Stockbridge Georgia 30281
Clinical Research Site Chevy Chase Maryland 20815
Clinical Research Site Kalamazoo Michigan 49008
Clinical Research Site Novi Michigan 48377
Clinical Research Site Neptune City New Jersey 07753
Clinical Research Site Denver North Carolina 28037
Clinical Research Site Gastonia North Carolina 28054
Clinical Research Site Huntersville North Carolina 28078
Clinical Research Site Cincinnati Ohio 45245
Clinical Research Site Wyomissing Pennsylvania 19610
Clinical Research Site Charleston South Carolina 29425
Clinical Research Site Columbia South Carolina 29201
Clinical Research Site Austin Texas 78731
Clinical Research Site San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05113745, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 12, 2025 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05113745 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →